1985 — The German drug licensing authority, the BGA, concludes that based on studies that show Prozac has no efficacy and significant negative side effects, including hallucinations, akathisia, psychosis, agitation and suicidality, it is "totally unsuitable for the treatment of depression." They refuse to approve this first selective serotonin reuptake inhibitor (SSRI) for Germans.